Literature DB >> 16007475

Activin A inhibits formation of skeletal muscle during chick development.

Liwen He1, Konstantin Vichev, Raymond Macharia, Ruijin Huang, Bodo Christ, Ketan Patel, Helge Amthor.   

Abstract

In this study we investigated the effect of recombinant activin A on the differentiation of limb muscle precursors of chick embryos. We show that treatment with activin resulted in a downregulation of Pax-3 and MyoD expression within 6 h after treatment, whereas expression of Myf-5 and Pax-7 was largely unaffected. The effect on gene expression was transient because 1 day after activin exposure the development of the premuscle masses had proceeded, and Pax-3 and MyoD expression was reexpressed at normal levels. Unlike other transforming growth factors-beta, activin did not induce programmed cell death in limb mesenchyme, thus myogenic cells were not permanently lost. In high-density cultures of embryonic chick limb mesenchyme (micromass cultures), activin repressed the generation of Pax-7-expressing muscle precursors. Furthermore, in the presence of activin, fewer muscle precursors differentiated, and the population of differentiating cells failed to fuse and form myotubes. Our data suggest that activin reversibly inhibited expression of two transcription factors, Pax-3 and MyoD, and thus transiently inhibited proliferation and differentiation of limb muscle precursors. However, myogenic cells were not lost as they continued to express Pax-7 and Myf-5, and this may have allowed precursors to commence development after the activin effect faded. We suggest that activin acts in conjunction with a closely related signalling molecule, myostatin, to prevent excessive growth of skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007475     DOI: 10.1007/s00429-005-0454-1

Source DB:  PubMed          Journal:  Anat Embryol (Berl)        ISSN: 0340-2061


  9 in total

1.  Myoblasts from intrauterine growth-restricted sheep fetuses exhibit intrinsic deficiencies in proliferation that contribute to smaller semitendinosus myofibres.

Authors:  Dustin T Yates; Derek S Clarke; Antoni R Macko; Miranda J Anderson; Leslie A Shelton; Marie Nearing; Ronald E Allen; Robert P Rhoads; Sean W Limesand
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

2.  Regulation of muscle mass by follistatin and activins.

Authors:  Se-Jin Lee; Yun-Sil Lee; Teresa A Zimmers; Arshia Soleimani; Martin M Matzuk; Kunihiro Tsuchida; Ronald D Cohn; Elisabeth R Barton
Journal:  Mol Endocrinol       Date:  2010-09-01

3.  Dual roles of smad proteins in the conversion from myoblasts to osteoblastic cells by bone morphogenetic proteins.

Authors:  Junya Nojima; Kazuhiro Kanomata; Yumi Takada; Toru Fukuda; Shoichiro Kokabu; Satoshi Ohte; Takatora Takada; Tohru Tsukui; Takamasa S Yamamoto; Hiroki Sasanuma; Katsumi Yoneyama; Naoto Ueno; Yasushi Okazaki; Ryutaro Kamijo; Tetsuya Yoda; Takenobu Katagiri
Journal:  J Biol Chem       Date:  2010-03-15       Impact factor: 5.157

4.  Extracellular Regulation of Myostatin: A Molecular Rheostat for Muscle Mass.

Authors:  Se-Jin Lee
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2010

5.  Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators.

Authors:  Tatyana A Souza; Xuan Chen; Yongjing Guo; Parid Sava; Jimin Zhang; Jennifer J Hill; Paul J Yaworsky; Yongchang Qiu
Journal:  Mol Endocrinol       Date:  2008-10-16

6.  Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells.

Authors:  Matthew Bowser; Samuel Herberg; Phonepasong Arounleut; Xingming Shi; Sadanand Fulzele; William D Hill; Carlos M Isales; Mark W Hamrick
Journal:  Exp Gerontol       Date:  2012-11-21       Impact factor: 4.032

7.  The MH1 domain of Smad3 interacts with Pax6 and represses autoregulation of the Pax6 P1 promoter.

Authors:  Timothy Grocott; Victoria Frost; Marjorie Maillard; Terje Johansen; Grant N Wheeler; Lucy J Dawes; I Michael Wormstone; Andrew Chantry
Journal:  Nucleic Acids Res       Date:  2007-01-23       Impact factor: 16.971

8.  A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.

Authors:  Qian Wang; Tingqing Guo; Jennifer Portas; Alexandra C McPherron
Journal:  Int J Biol Sci       Date:  2015-01-05       Impact factor: 6.580

9.  Redundancy of myostatin and growth/differentiation factor 11 function.

Authors:  Alexandra C McPherron; Thanh V Huynh; Se-Jin Lee
Journal:  BMC Dev Biol       Date:  2009-03-19       Impact factor: 1.978

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.